



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 31/435, 31/47, 31/535, 31/57, A61P 27/02, 27/16, A61K 45/06 // (A61K 31/57, 31:535) (A61K 31/57, 31:47)	A3	(11) International Publication Number: WO 00/18386 (43) International Publication Date: 6 April 2000 (06.04.00)
(21) International Application Number: PCT/US99/22622 (22) International Filing Date: 29 September 1999 (29.09.99) (30) Priority Data: 60/102,504 30 September 1998 (30.09.98) US 60/102,506 30 September 1998 (30.09.98) US (71) Applicant (for all designated States except US): ALCON LABORATORIES, INC. [US/US]; 6201 South Freeway, Mail Code Q-148, Fort Worth, TX 76134-2099 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): CAGLE, Gerald [US/US]; No. 6309 Greenway, Fort Worth, TX 76116 (US). AB- SHIRE, Robert, L. [US/US]; 3001 Gunnison Trail, Fort Worth, TX 76116 (US). STROMAN, David, W. [US/US]; 2603 Waterford, Irving, TX 75063 (US). YANNI, John, M. [US/US]; 2821 Donnybrook Drive, Burleson, TX 76028 (US). (74) Agents: BROWN, Gregg, C. et al.; Alcon Laboratories, Inc., R & D Counsel, Mail Code Q-148, 6201 South Freeway, Fort Worth, TX 76134-2099 (US).		(81) Designated States: AU, BR, CA, CN, JP, KR, MX, TR, US, ZA, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> (88) Date of publication of the international search report: 8 June 2000 (08.06.00)
(54) Title: ANTIBIOTIC COMPOSITIONS FOR TREATMENT OF THE EYE, EAR AND NOSE		
(57) Abstract Ophthalmic, otic and nasal compositions containing a new class of antibiotics (e.g., moxifloxacin) are disclosed. The compositions preferably also contain one or more anti-inflammatory agents. The compositions may be utilized to treat ophthalmic, otic and nasal conditions by topically applying the compositions to the affected tissues.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**ANTIBIOTIC COMPOSITIONS FOR
TREATMENT OF THE EYE, EAR AND NOSE**

Background of the Invention

10 The present invention is directed to the provision of topical antibiotic pharmaceutical compositions for the treatment of ophthalmic, otic and nasal infections, particularly bacterial infections, and to methods of treating ophthalmic, otic and nasal infections by applying those compositions to the affected tissues. The compositions and methods of the invention are based on the use of a new class of antibiotics. The
15 compositions of the present invention may also contain one or more anti-inflammatory agents.

 The use of quinolone antibiotics to treat infections represents the current state of the art in the field of ophthalmic pharmaceutical compositions and methods of treatment.
20 For example, a topical ophthalmic composition containing the quinolone ciprofloxacin is marketed by Alcon Laboratories, Inc. under the name CILOXAN™ (Ciprofloxacin 0.3%) Ophthalmic Solution. The following quinolones have also been utilized in ophthalmic antibiotic compositions:

<u>Quinolone</u>	<u>Product</u>	<u>Manufacturer</u>
Ofloxacin	OCUFLOX™	Allergan
Norfloxacin	CHIBROXIN™	Merck
Lomefloxacin	LOMEFLOX™	Senju

25

 The foregoing quinolone antibiotic compositions are generally effective in treating ophthalmic infections, and have distinct advantages over prior ophthalmic antibiotic compositions, particularly those having relatively limited spectrums of antimicrobial activity, such as: neomycin, polymyxin B, gentamicin and tobramycin,

which are primarily useful against gram negative pathogens; and bacitracin, gramicidin, and erythromycin, which are primarily active against gram positive pathogens. However, despite the general efficacy of the ophthalmic quinolone therapies currently available, there is a need for improved compositions and methods of treatment based on the use of antibiotics that are more effective than existing antibiotics against key ophthalmic pathogens, and less prone to the development of resistance by those pathogens.

There is an even greater need for effective topical compositions and methods for treating otic and nasal infections, particularly bacterial infections. The use of oral antibiotics to treat otic infections in children has limited efficacy, and creates a serious risk of pathogen resistance to the orally administered antibiotics.

Ophthalmic, otic and nasal infections are frequently accompanied by inflammation of the infected ophthalmic, otic and nasal tissues and perhaps even surrounding tissues. Similarly, ophthalmic, otic and nasal surgical procedures that create a risk of microbial infections frequently also cause inflammation of the affected tissues. Thus, there is also a need for ophthalmic, otic and nasal pharmaceutical compositions that combine the anti-infective activity of one or more antibiotics with the anti-inflammatory activity of one or more steroid or non-steroid agents in a single composition.

Summary of the Invention

The invention is based on the use of a potent new class of antibiotics to treat ophthalmic, otic and nasal infections, as well as the prophylactic use of these antibiotics following surgery or other trauma to ophthalmic, otic or nasal tissues. The compositions of the present invention may also be administered to the affected tissues during ophthalmic, otic or nasal surgical procedures to prevent or alleviate post-surgical infection.

The compositions preferably also contain one or more anti-inflammatory agents to treat inflammation associated with infections of ophthalmic, otic or nasal tissues. The

anti-inflammatory component of the compositions is also useful in treating inflammation associated with physical trauma to ophthalmic, otic or nasal tissues, including inflammation resulting from surgical procedures. The compositions of the present invention are therefore particularly useful in treating inflammation associated with
5 trauma to ophthalmic, otic or nasal tissues wherein there is either an infection or a risk of an infection resulting from the trauma.

Examples of ophthalmic conditions that may be treated with the compositions of the present invention include conjunctivitis, keratitis, blepharitis, dacryocystitis,
10 hordeolum and corneal ulcers. The compositions of the invention may also be used prophylactically in connection with various ophthalmic surgical procedures that create a risk of infection.


Examples of otic conditions that may be treated with the compositions of the present invention include otitis externa and otitis media. With respect to the treatment of
15 otitis media, the compositions of the present invention are primarily useful in cases where the tympanic membrane has ruptured or tympanostomy tubes have been implanted. The compositions may also be used to treat infections associated with otic surgical procedures, such as tympanostomy, or to prevent such infections.

20

The compositions of the present invention are specially formulated for topical application to ophthalmic, otic and nasal tissues. The compositions are preferably sterile, and have physical properties (e.g., osmolality and pH) that are specially suited for application to ophthalmic, otic and nasal tissues, including tissues that have been
25 compromised as the result of preexisting disease, trauma, surgery or other physical conditions.

Detailed Description of the Invention

The antibiotics used in the compositions and methods of the present invention have the following formula:



wherein:


A is CH, CF, CCl, C-OCH₃, or N;

X¹ is H, halogen, NH₂, or CH₃;

R¹ is C₁ to C₃ alkyl, FCH₂CH₂, cyclopropyl or phenyl, optionally mono-, di- or tri-substituted by halogen, or A and R₁ together can form a bridge of formula C-O-CH₂-CH(CH₃);

R² is H, C₁ to C₃ alkyl (optionally substituted by OH, halogen or NH₂), or 5-methyl-2-oxo-1,3-dioxol-4-yl-methyl; and

B is selected from the group consisting of:



wherein:

Y is O or CH₂;

5 R³ is C₂-C₅ alkoxyl, CH₂-CO-C₆H₅, CH₂CH₂CO₂R', R'O₂C-CH=C-CO₂R',
CH=CH-CO₂R' or CH₂CH₂-CN,

wherein:

10 R' is H or C₁ to C₃ alkyl;

R⁴ is H, C₁ to C₃ alkyl, C₂-C₅ alkoxyl, CH₂-CO-C₆H₅, CH₂CH₂CO₂R',
R'O₂C-CH=C-CO₂R', CH=CH-CO₂R', CH₂CH₂-CN or 5-methyl-2-oxo-
1,3-dioxol-4-yl-methyl,

15

wherein:


R' is H or C₁ to C₃ alkyl; and

20 their pharmaceutically useful hydrates and salts.

The compound Moxifloxacin is most preferred. Moxifloxacin has the following
structure:

25

30



35

Further details regarding the structure, preparation, and physical properties of
Moxifloxacin and other compounds of formula (I) are provided in United States Patent
No. 5,607,942.

The concentrations of the antibiotics of formula (I) in the compositions of the
present invention will vary depending on the intended use of the compositions (e.g.,
treatment of existing infections or prevention of post-surgical infections), and the relative

antimicrobial activity of the specific antibiotic selected. The antimicrobial activity of antibiotics is generally expressed as the minimum concentration required to inhibit the growth of a specified pathogen. This concentration is also referred to as the "minimum inhibitory concentration" or "MIC". The term "MIC₉₀" refers to the minimum concentration of antibiotic required to inhibit the growth of ninety percent (90%) of the strains of a species. The concentration of an antibiotic required to totally kill a specified bacteria is referred to as the "minimum bactericidal concentration" or "MBC". The minimum inhibitory concentration of Moxifloxacin for several bacteria commonly associated with ophthalmic, otic and nasal infections are provided in the following table:

10

	<u>Microorganism</u>	<u>MIC₉₀</u>
	S. aureus/methicillin sensitive	0.13
	S. aureus/methicillin resistant	4.0
15	S. aureus/quinolone resistant	4.0
	S. epidermidis/methicillin sensitive	0.25
	S. epidermidis/methicillin resistant	4.0
	S. pneumoniae/penicillin sensitive	0.25
	S. pneumoniae/penicillin resistant	0.25
20	P. aeruginosa	8.0
	H. influenzae/ β -lactamase positive	0.06
	H influenzae/ β lactamase negative	0.06

All of the foregoing concentrations are expressed as micrograms per milliliter ("mcg/ml").

25


The appropriate antibiotic concentration for ophthalmic compositions will generally be an amount of one or more antibiotics of formula (I) sufficient to provide a concentration in the aqueous humor and lacrimal fluid of the eye equal to or greater than the MIC90 level for the selected antibiotic(s), relative to gram-negative and gram-positive organisms commonly associated with ophthalmic infections. The appropriate concentration for otic and nasal compositions will generally be an amount of one or more antibiotics of formula (I) sufficient to provide a concentration in the infected tissues equal to or greater than the MIC90 level for the selected antibiotic(s), relative to gram-negative and gram-positive organisms commonly associated with otic or nasal infections.

Such amounts are referred to herein as "an antimicrobial effective amount". The compositions of the present invention will typically contain one or more compounds of formula (I) in a concentration of from about 0.1 to about 1.0 percent by weight ("wt. %") of the compositions.


The compositions of the present invention may also contain one or more anti-inflammatory agents. The anti-inflammatory agents utilized in the present invention are broadly classified as steroidal or non-steroidal. The preferred steroidal anti-inflammatory agents are glucocorticoids.

The preferred glucocorticoids for ophthalmic and otic use include dexamethasone, loteprednol, rimexolone, prednisolone, fluorometholone, and hydrocortisone. The preferred glucocorticoids for nasal use include mometasone, fluticasone, beclomethasone, flunisolide, triamcinolone and budesonide.

The dexamethasone derivatives described in U.S. Patent No. 5,223,493 (Boltralik) are also preferred steroidal anti-inflammatory agents, particularly with respect to compositions for treating ophthalmic inflammation. The following compounds are especially preferred:



AL-1529



AL-2512

These compounds are referred to herein as "21-ether derivatives of dexamethasone". The 21-benzyl ether derivative (i.e., compound AL-2512) is particularly preferred.

5

The preferred non-steroidal anti-inflammatory agents are: prostaglandin H synthetase inhibitors (Cox I or Cox II), also referred to as cyclooxygenase type I and type II inhibitors, such as diclofenac, flurbiprofen, ketorolac, suprofen, nepafenac, amfenac, indomethacin, naproxen, ibuprofen, bromfenac, ketoprofen, meclofenamate, piroxicam, sulindac, mefenamic acid, diflusal, oxaprozin, tolmetin, fenoprofen, benoxaprofen, nabumetome, etodolac, phenylbutazone, aspirin, oxyphenbutazone, NCX-4016, HCT-1026, NCX-284, NCX-456, tenoxicam and carprofen; cyclooxygenase type II selective inhibitors, such as NS-398, viox, celecoxib, P54, etodolac, L-804600 and S-33516; PAF antagonists, such as SR-27417, A-137491, ABT-299, apafant, bepafant, minopafant, E-6123, BN-50727, nupafant and modipafant; PDE IV inhibitors, such as ariflo, torbafylline, rolipram, filaminast, piclamilast, cipamfylline, CG-1088, V-11294A, CT-2820, PD-168787, CP-293121, DWP-205297, CP-220629, SH-636, BAY-19-8004, and roflumilast; inhibitors of cytokine production, such as inhibitors of the NFkB transcription factor; or other anti-inflammatory agents known to those skilled in the art.

20

The concentrations of the anti-inflammatory agents contained in the compositions of the present invention will vary based on the agent or agents selected and the type of inflammation being treated. The concentrations will be sufficient to reduce inflammation in the targeted ophthalmic, otic or nasal tissues following topical application of the compositions to those tissues. Such an amount is referred to herein as "an anti-inflammatory effective amount". The compositions of the present invention will typically contain one or more anti-inflammatory agents in an amount of from about 0.01 to about 1.0 wt.%. 5

The compositions are typically administered to the affected ophthalmic, otic or nasal tissues by topically applying one to four drops of a sterile solution or suspension, or a comparable amount of an ointment, gel or other solid or semisolid composition, one to four times per day. However, the compositions may also be formulated as irrigating solutions that are applied to the affected ophthalmic, otic or nasal tissues during surgical procedures. 10

The ophthalmic, otic and nasal compositions of the present invention will contain one or more compounds of formula (I) and preferably one or more anti-inflammatory agents, in pharmaceutically acceptable vehicles. The compositions will typically have a pH in the range of 4.5 to 8.0. The ophthalmic compositions must also be formulated to have osmotic values that are compatible with the aqueous humor of the eye and ophthalmic tissues. Such osmotic values will generally be in the range of from about 200 to about 400 milliosmoles per kilogram of water ("mOsm/kg"), but will preferably be about 300 mOsm/kg. 15 20

Ophthalmic, otic and nasal pharmaceutical products are typically packaged in multidose form. Preservatives are thus required to prevent microbial contamination during use. Suitable preservatives include: polyquaternium-1, benzalkonium chloride, thimerosal, chlorobutanol, methyl paraben, propyl paraben, phenylethyl alcohol, edetate disodium, sorbic acid, or other agents known to those skilled in the art. The use of polyquaternium-1 as the antimicrobial preservative is preferred. Typically such preservatives are employed at a level of from 0.001% to 1.0% by weight. 25 30

The solubility of the components of the present compositions may be enhanced by a surfactant or other appropriate co-solvent in the composition. Such co-solvents include polysorbate 20, 60, and 80, polyoxyethylene/polyoxypropylene surfactants (e.g., Pluronic F-68, F-84 and P-103), cyclodextrin, or other agents known to those skilled in the art.

5 Typically such co-solvents are employed at a level of from 0.01% to 2% by weight.

The use of viscosity enhancing agents to provide the compositions of the invention with viscosities greater than the viscosity of simple aqueous solutions may be desirable to increase ocular absorption of the active compounds by the target tissues or increase the retention time in the eye, ear or nose. Such viscosity building agents include, for example, polyvinyl alcohol, polyvinyl pyrrolidone, methyl cellulose, hydroxy propyl methylcellulose, hydroxyethyl cellulose, carboxymethyl cellulose, hydroxy propyl cellulose or other agents known to those skilled in the art. Such agents are typically

15 employed at a level of from 0.01% to 2% by weight.

The following examples are provided to further illustrate the ophthalmic, otic and nasal compositions of the present invention.

20

Example 1**Ophthalmic/Otic/Nasal Solution**

25

30

<u>Ingredient</u>	<u>Amount (wt. %)</u>
Moxifloxacin	0.35
Sodium Acetate	0.03
Acetic Acid	0.04
Mannitol	4.60
EDTA	0.05
Benzalkonium Chloride	0.006
Water	q.s. 100

Example 2**Ophthalmic/Otic/Nasal Suspension**

	<u>Ingredient</u>	<u>Amount (wt. %)</u>
5	Moxifloxacin	0.3
	Dexamethasone, Micronized USP	0.10
	Benzalkonium Chloride	0.01
	Edetate Disodium, USP	0.01
	Sodium Chloride, USP	0.3
10	Sodium Sulfate, USP	1.2
	Tyloxapol, USP	0.05
	Hydroxyethylcellulose	0.25
	Sulfuric Acid and/or	
	Sodium Hydroxide, NF	q.s. for pH adjustment to 5.5
15	Purified Water, USP	q.s. to 100

Example 3**Ophthalmic Ointment**

20	<u>Ingredient</u>	<u>Amount (wt.%)</u>
	Moxifloxacin	0.35
	Mineral Oil, USP	2.0
	White petrolatum, USP	q.s 100


Example 4**Ophthalmic Ointment**

<u>Ingredient</u>	<u>Amount (wt.%)</u>
Moxifloxacin	0.3
Fluorometholone Acetate, USP	0.1
Chlorobutanol, Anhydrous, NF	0.5
Mineral Oil, USP	5
White Petrolatum, USP	q.s. 100

10 The invention has been described herein by reference to certain preferred embodiments. However, as obvious variations thereon will become apparent to those skilled in the art, the invention is not to be considered as limited thereto.

What is claimed is:

1. A topical ophthalmic, otic or nasal pharmaceutical composition comprising an antimicrobial effective amount of one or more compounds of the formula:



wherein:


A is CH, CF, CCl, C-OCH₃, or N;

X¹ is H, halogen, NH₂, or CH₃;

R¹ is C₁ to C₃ alkyl, FCH₂CH₂, cyclopropyl or phenyl, optionally mono-, di- or tri-substituted by halogen, or A and R₁ together can form a bridge of formula C-O-CH₂-CH(CH₃);

R² is H, C₁ to C₃ alkyl (optionally substituted by OH, halogen or NH₂), or 5-methyl-2-oxo-1,3-dioxol-4-yl-methyl; and

B is selected from the group consisting of:



wherein:

Y is O or CH₂;

5 R³ is C₂-C₅ alkoxyl, CH₂-CO-C₆H₅, CH₂CH₂CO₂R', R'O₂C-CH=C-CO₂R',
CH=CH-CO₂R' or CH₂CH₂-CN,

wherein:

10 R' is H or C₁ to C₃ alkyl;

R⁴ is H, C₁ to C₃ alkyl, C₂-C₅ alkoxyl, CH₂-CO-C₆H₅, CH₂CH₂CO₂R',
R'O₂C-CH=C-CO₂R', CH=CH-CO₂R', CH₂CH₂-CN or 5-methyl-2-oxo-1,3-
15 dioxol-4-yl-methyl,

wherein:

R' is H or C₁ to C₃ alkyl; and

20 their pharmaceutically useful hydrates and salts; and a pharmaceutically acceptable vehicle therefor.

2. A topical composition according to Claim 1, wherein the composition further
25 comprises an anti-inflammatory effective amount of a steroidal or non-steroidal anti-inflammatory agent.

3. A topical composition according to Claim 2, wherein the anti-inflammatory agent
comprises a glucocorticoid.

30

4. A topical composition according to Claim 3, wherein the glucocorticoid is
selected from the group consisting of dexamethasone, rimexolone, prednisolone,
fluorometholone, hydrocortisone, mometasone, fluticasone, beclomethasone, flunisolide,
triamcinolone and budesonide.

35

5. A topical composition according to Claim 2, wherein the anti-inflammatory agent
comprises a non-steroidal agent selected from the group consisting of prostaglandin H
synthetase inhibitors, PAF antagonists, and PDE IV inhibitors.

6. A topical composition according to Claim 2, wherein the compound of formula (I) comprises moxifloxacin.

7. A topical composition according to Claim 6, wherein the anti-inflammatory agent
5 comprises dexamethasone.

8. A method of treating or preventing ophthalmic, otic or nasal infections, which comprises topically applying a therapeutically effective amount of the composition of Claim 1 to the affected ophthalmic, otic or nasal tissue.

10

9. A method of treating or preventing ophthalmic, otic or nasal infections and attendant inflammation, which comprises topically applying a therapeutically effective amount of the composition of Claim 2 to the affected ophthalmic, otic or nasal tissue.

15 10. A method of treating or preventing ophthalmic, otic or nasal infections and attendant inflammation, which comprises topically applying a therapeutically effective amount of the composition of Claim 6 to the affected ophthalmic, otic or nasal tissue.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/22622

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/435 A61K31/47 A61K31/535 A61K31/57 A61P27/02
A61P27/16 A61K45/06 //(A61K31/57,31:535),(A61K31/57,31:47)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 90 01933 A (ALCON LAB INC) 8 March 1990 (1990-03-08) the whole document	1-10
Y	WO 96 39146 A (BAYER AG) 12 December 1996 (1996-12-12) the whole document	1-10
X	US 5 607 942 A (PETERSEN UWE ET AL) 4 March 1997 (1997-03-04) cited in the application	1,6,8,10
Y	column 56, line 27-30	1-10
X	US 4 990 517 A (PETERSEN UWE ET AL) 5 February 1991 (1991-02-05)	1,6,8,10
Y	column 59, line 19-22; claims	1-10
	-/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "Z" document member of the same patent family

Date of the actual completion of the international search

28 March 2000

Date of mailing of the international search report

05/04/2000

Name and mailing address of the ISA

European Patent Office, P.B. 6818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

V ronese, A

INTERNATIONAL SEARCH REPORT

Inter national Application No

PCT/US 99/22622

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 550 903 A (BAYER AG) 14 July 1993 (1993-07-14) page 22, line 56 -page 23, line 6; claims	
A	DE 44 24 369 A (BAYER AG) 18 January 1996 (1996-01-18) the whole document	1-10
P,Y	WO 99 15172 A (KETTELHOIT STEFAN ;SIEFERT HANS MARTIN (DE); STASS HEINO (DE); BAY) 1 April 1999 (1999-04-01) the whole document	1-10
A	US 5 223 493 A (BOLTRALIK JOHN J) 29 June 1993 (1993-06-29) cited in the application the whole document	1-10
P,X	KRASEMANN, C. (1) ET AL: "Efficacy of moxifloxacin against Staphylococcus aureus in respiratory tract and skin and skin structure infections." JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, (JULY, 1999) VOL. 44, NO. SUPPL. A, PP. 150. MEETING INFO.: 21ST INTERNATIONAL CONGRESS OF CHEMOTHERAPY BIRMINGHAM, ENGLAND, UK JULY 4-7, 1999 , XP000892776 the whole document	1,6,8,10
A	ELIES W.: "Novel fluoroquinolones in the treatment of ENT infections!. NEUERE FLUORCHINOLONE BEI DER THERAPIE VON HNO-INFESTIONEN." CHEMOTHERAPIE JOURNAL, (1998) 7/3 (93-97). , XP000892813 page 95, column 1	1,6,8,10

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/ 22622

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
SEE FURTHER INFORMATION SHEET PCT/ISA/210
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 8-10 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Markush formula in claim 1 contains an obvious error: position 8 in the quinolone structure should be group "A". The search was carried out taking into account the correct structure.

INTERNATIONAL SEARCH REPORT

information on patent family members

Inter. Appl. No.

PCT/US 99/22622

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9001933 A	08-03-1990	AU 4201189 A	23-03-1990
WO 9639146 A	12-12-1996	AU 708540 B	05-08-1999
		AU 5984096 A	24-12-1996
		CA 2199294 A	12-12-1996
		EP 0782448 A	09-07-1997
		NZ 309624 A	29-04-1999
		US 5965549 A	12-10-1999
		US 5843930 A	01-12-1998
		ZA 9604653 A	12-12-1996
US 5607942 A	04-03-1997	DE 3906365 A	18-01-1990
		US 5416096 A	16-05-1995
		AT 157094 T	15-09-1997
		AU 650316 B	16-06-1994
		AU 658667 B	27-04-1995
		AU 2528692 A	26-11-1992
		AU 668286 B	26-04-1996
		AU 6055694 A	09-06-1994
		AU 668287 B	26-04-1996
		AU 6055794 A	09-06-1994
		AU 671386 B	22-08-1996
		AU 7299194 A	08-12-1994
		CA 1340114 A	03-11-1998
		CN 1039589 A,B	14-02-1990
		CN 1097759 A,B	25-01-1995
		CN 1143080 A	19-02-1997
		DD 285601 A	19-12-1990
		DE 58909622 D	25-09-1997
		DK 350089 A	16-01-1990
		EP 0350733 A	17-01-1990
		EP 0757990 A	12-02-1997
		ES 2109219 T	16-01-1998
		FI 893403 A,B,	16-01-1990
		GR 3024841 T	30-01-1998
		HK 1000938 A	08-05-1998
		HU 52087 A,B	28-06-1990
		HU 65936 A,B	29-08-1994
		HU 9500442 A	28-09-1995
		IL 90940 A	12-04-1994
		JP 10182600 A	07-07-1998
		JP 2069474 A	08-03-1990
		JP 2771853 B	02-07-1998
		KR 156238 B	16-11-1998
		KR 156375 B	01-10-1998
		MX 9203609 A	01-07-1992
		NO 892715 A,B,	16-01-1990
		NZ 229914 A	26-03-1992
		NZ 239485 A	26-03-1992
		PH 26723 A	15-09-1992
		PT 91165 A,B	08-02-1990
		US 4990517 A	05-02-1991
		US 5059597 A	22-10-1995
		ZA 8905366 A	25-04-1990
US 4990517 A	05-02-1991	DE 3906365 A	18-01-1990
		AT 157094 T	15-09-1997
		AU 650316 B	16-06-1994

INTERNATIONAL SEARCH REPORT

Information on patent family members

Initial Application No

PCT/US 99/22622

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4990517 A		AU 658667 B	27-04-1995
		AU 2528692 A	26-11-1992
		AU 668286 B	26-04-1996
		AU 6055694 A	09-06-1994
		AU 668287 B	26-04-1996
		AU 6055794 A	09-06-1994
		AU 671386 B	22-08-1996
		AU 7299194 A	08-12-1994
		CA 1340114 A	03-11-1998
		CN 1039589 A,B	14-02-1990
		CN 1097759 A,B	25-01-1995
		CN 1143080 A	19-02-1997
		DD 285601 A	19-12-1990
		DE 58909622 D	25-09-1997
		DK 350089 A	16-01-1990
		EP 0350733 A	17-01-1990
		EP 0757990 A	12-02-1997
		ES 2109219 T	16-01-1998
		FI 893403 A,B,	16-01-1990
		GR 3024841 T	30-01-1998
		HK 1000938 A	08-05-1998
		HU 52087 A,B	28-06-1990
		HU 65936 A,B	29-08-1994
		HU 9500442 A	28-09-1995
		IL 90940 A	12-04-1994
		JP 10182600 A	07-07-1998
		JP 2069474 A	08-03-1990
		JP 2771853 B	02-07-1998
		KR 156238 B	16-11-1998
		KR 156375 B	01-10-1998
		MX 9203609 A	01-07-1992
		NO 892715 A,B,	16-01-1990
		NZ 229914 A	26-03-1992
		NZ 239485 A	26-03-1992
		PH 26723 A	15-09-1992
		PT 91165 A,B	08-02-1990
		US 5607942 A	04-03-1997
		US 5059597 A	22-10-1991
		US 5416096 A	16-05-1995
		ZA 8905366 A	25-04-1990
EP 0550903 A	14-07-1993	DE 4200414 A	15-07-1993
		DE 4208789 A	23-09-1993
		DE 4208792 A	23-09-1993
		AU 669502 B	13-06-1996
		AU 3105493 A	15-07-1993
		CA 2086914 A	11-07-1993
		CN 1074218 A,B	14-07-1993
		CN 1192440 A	09-09-1998
		CN 1212256 A	31-03-1999
		FI 930049 A	11-07-1993
		FI 971012 A	11-03-1997
		FI 990207 A	03-02-1999
		HU 64065 A	29-11-1993
		IL 104331 A	10-01-1997
		JP 5271229 A	19-10-1993
		MX 9207604 A	01-10-1993
		NO 301420 B	27-10-1997

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/US 99/22622

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0550903 A		NZ 245640 A PL 174853 B PL 175558 B ZA 9300125 A	28-03-1995 30-09-1998 29-01-1999 10-08-1993
DE 4424369 A	18-01-1996	AU 684651 B AU 2925695 A BR 9508384 A CA 2194694 A CN 1152921 A CZ 9700056 A WO 9601829 A EP 0770083 A FI 970092 A HU 77138 A JP 10502377 T NO 970079 A NZ 289419 A PL 318097 A SK 2797 A US 5854241 A ZA 9505707 A	18-12-1997 09-02-1996 23-12-1997 25-01-1996 25-06-1997 14-05-1997 25-01-1996 02-05-1997 09-01-1997 02-03-1998 03-03-1998 09-01-1997 24-09-1998 12-05-1997 09-07-1997 29-12-1998 21-02-1996
WO 9915172 A	01-04-1999	AU 9348498 A	12-04-1999
US 5223493 A	29-06-1993	CA 2140345 A US 5446177 A AU 4379093 A EP 0650496 A WO 9426769 A	24-11-1994 29-08-1995 12-12-1994 03-05-1995 24-11-1994